Jeffrey L. Clark |
 |
Northwestern University Law School, JD, 1982 Matt joined the firm as Of Counsel in 2009, with twenty-six years of experience in patent procurement, licensing and opinion matters crossing several different industries. His practice is presently centered in the San Francisco Bay area of California. For the past fifteen years, Matt has focused primarily on providing strategic business advice, as in-house counsel, to the senior leadership at several biotech, pharmaceutical and healthcare entities, large and small. Before transitioning to the biopharmaceutical arena, Matt served as senior patent counsel in the Patents and Licensing Department of Amoco Corporation (Now BP America), from 1985 to 1994, where he developed an extensive portfolio in engineered polymers, chemical intermediates and polymeric fiber technology. Matt joined the patent and trademark department of Abbott Laboratories in 1994 where he held supervisory positions supporting the diagnostic and pharmaceutical businesses of Abbott. In 2000, Matt became Senior Patent Counsel at Scios, Inc., a small biotech company in the Silicon Valley working on a number of breakthrough technologies. In 2001, the company's acute heart failure drug, Natrecor® (nesiritide), was one of the most successful cardiac drugs ever launched. In 2001, Matt became the company's Vice-President and General Counsel, managing all of its legal affairs, and eventually playing a significant role in the company's 2003 merger into Johnson & Johnson. Most recently, Matt served until 2006 as an Assistant General Counsel at Johnson & Johnson, and then until 2008 as Vice President and General Counsel at Halozyme Therapeutics in San Diego, a small biopharma company specializing in drug delivery technologies designed to enhance the delivery of various existing therapies, including large biological drugs, pediatric hydration fluids, cancer drugs, and insulin. From the breadth and depth of his in-house experience, Matt understands the pace and rhythm of small entities that are unrelenting in their quest to launch novel therapies. In this unique environment, he has developed a finely-tuned ear to the challenges of guiding senior management (and in-house legal practitioners) with strategic advice that is business-driven, clear and timely. |
|
|||||